Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
NCT04093167Phase 3Active, not recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- May 2020
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoints: Concordance rate between molecular response and radiologic response at 18 months, Progression-Free Survival at 3 years and 1 more. Started May 2020; status: active, not recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04093167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04093167.